2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes
NVVC (Netherlands Society of Cardiology) · 2026 · Netherlands
Source and licence
- Authors
- Alexander Hirsch, Leo H. B. Baur, Peter Damman et al.
- Title
- 2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes
- Journal
- Netherlands Heart Journal, 2026
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC13376111
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
Verbatim, with grade of recommendation or strength of consensus where given.
Drafting of this addendum:
- The working group assessed all recommendations from the guideline for applicability in the Netherlands. All recommendations were assessed during several meetings. In particular, recommendations with a low level of evidence (level of evidence C; expert opinion) are assessed for applicability in the Dutch clinical setting. Recommendations with a higher level of evidence can be changed only in light of new literature or changes in Dutch cardiology practice. Any modifications to the recommendations were agreed upon by consensus. An overview highlighting several comments from the working group is depicted in Tab. 1.
Abstract
This article discusses the updated 2024 European Society of Cardiology guidelines on chronic coronary syndromes and situates them within the context of Dutch clinical practice. A working group was appointed by the Netherlands Society of Cardiology (Nederlandse Vereniging voor Cardiologie). It consisted of a general cardiologist, interventional cardiologists, cardiovascular imaging cardiologists, and a representative of the Dutch Heart Foundation (Nederlandse Hartstichting). This document summarizes the key recommendations and includes additional guidance tailored to clinical practice in the Netherlands, focusing on the risk-factor-weighted clinical likelihood model, the choice of non-invasive imaging modality, functional assessment of epicardial artery stenosis during invasive coronary angiography, and angina and ischemia with non-obstructive coronary arteries. It is intended for all healthcare professionals involved in the care of patients with chronic coronary syndromes and has been approved by the Netherlands Society of Cardiology and the Dutch Heart Foundation.
Contents of the original publication
The section headings of the original.
- Introduction
- Methods
- Composition of the working group:
- Drafting of this addendum:
- Comment and authorization phase:
- Summary and translation into clinical practice in the Netherlands
- The stepwise approach to the initial management of individuals with suspected chronic coronary syndrome
- Guideline-directed therapy
- Optimal assessment and treatment of specific groups
- Patient-centered care and shared decision-making
- Conclusion
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint